DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for De Quervain disease — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDe Quervain disease maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for de quervain disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
In a retrospective study of 319 wrists in 300 patients followed for one to six years, patients with minimal symptoms were mostly relieved by splinting plus oral NSAIDs (15 of 17), but only 7 of 20 with mild symptoms and 2 of 8 with moderate or severe symptoms were relieved by that same regimen. Among 249 patients with moderate or severe symptoms treated with steroid injection, 76% were completely relieved, 7% improved, and 4% were not improved. A 2023 randomised trial of 60 patients in Bangladesh (mean age 41.8 years, 7.6 females per male) compared intralesional methylprednisolone acetate injection (20 mg plus lidocaine) to a thumb spica splint in moderate to severe disease. Over six weeks, injection gave pain relief in 83.33% of patients versus 36.67% in the splint group, with significant differences in VAS and PRWE scores at each follow-up (p<0.001).
A 2020 systematic review of 66 articles reported that corticosteroid injection success rates range from 61% to 83% across studies, and that a multimodal approach combining splint therapy with injections appears more beneficial than either alone. The review noted some evidence that multi-point injection techniques and multiple injections before surgical referral may provide benefit over single-point injection and a single injection before surgery, but cautioned that corticosteroid use is not benign. Ultrasound-guided injections were shown to be more accurate and to confer better outcomes, and ultrasound was found valuable for visualising an intercompartmental septum.
The 2023 trial found that 53% of patients had right-hand involvement, 42% left, and 5% both. No significant difference in pretreatment scores existed between groups. The retrospective study from 2001 proposed that pre-treatment symptom classification may help select treatment and provide prognosis. The 2020 review concluded that a Level I to II evidence-based treatment protocol is recommended for optimal nonsurgical management, but noted that several prior and concurrent medical conditions may affect conservative treatment outcome.
What remains missing is a standardised, prospectively validated classification system that reliably predicts which patients will respond to splinting versus injection, and clear evidence on the optimal number and timing of injections before surgical referral. No cost-effectiveness data comparing injection, splinting, and combined approaches were provided in these abstracts, and the 2023 trial was limited to six weeks of follow-up in a single centre in Bangladesh.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Hand Surgery (European Volume) · 2001 · 140 citations
Treatment of De Quervain’s Disease: Role of Conservative Management
AbstractThis retrospective study compares two methods used to treat de Quervain's disease: splintage with oral non-steroidal anti-inflammatory drugs (NSAIDs) and steroid injection. Patients were separated into three groups based on symptom severity: group I-minimal, group II-mild, and group III-moderate or severe. Three hundred and nineteen wrists in 300 patients were followed from one to six years. Fifteen of 17 patients with minimal symptoms were relieved with splintage and NSAIDs. However, only seven of 20 in Group II and two of eight in Group III treated similarly were relieved. Of the 249 patients in Group III treated with injections, 76% were completely relieved, 7% were improved, and 4% were not improved. We conclude that classification of patients' with de Quervain's disease based on their pre-treatment symptoms may assist surgeons in selecting the most efficacious treatment and in providing prognostic information to their patients.
Plastic & Reconstructive Surgery · 2020 · 37 citations
Conservative Management of de Quervain Stenosing Tenosynovitis: Review and Presentation of Treatment Algorithm
AbstractBACKGROUND: Nonsurgical management of de Quervain disease relies mainly on the use of oral nonsteroidal antiinflammatory drug administration, splint therapy, and corticosteroid injections. Although the latter is most effective, with documented success rates of 61 to 83 percent, there exists no clear consensus pertaining to conservative treatment protocols conferring the best outcomes. This article reports on all present conservative treatment modalities in use for the management of de Quervain disease and highlights specific treatment- and patient-related factors associated with the best outcomes. METHODS: A systematic search was performed using the PubMed database using appropriate search terms; two independent reviewers evaluated retrieved articles using strict inclusion and exclusion criteria. RESULTS: A total of 66 articles met the inclusion criteria for review, consisting of 22 articles reporting on outcomes following a single conservative treatment modality, eight articles reporting on combined treatment approaches, 13 articles directly comparing different conservative treatment regimens, and 23 case reports. CONCLUSIONS: A multimodal approach using splint therapy and corticosteroid injections appears to be more beneficial than either used in isolation. Although there exists some evidence showing that multipoint injection techniques and multiple injections before surgical referral may provide benefit over a single point injection technique and a single injection before surgery, corticosteroid use is not benign and should thus be performed with caution. Ultrasound was proven valuable in the visualization of an intercompartmental septum, and ultrasound-guided injections were shown to both be more accurate and confer better outcomes. Several prior and concurrent medical conditions may affect conservative treatment outcome. A Level I to II evidence-based treatment protocol is recommended for the optimal nonsurgical management of de Quervain disease.
TAJ Journal of Teachers Association · 2023 · 0 citations · open access
Comparative Study between Intralesional Steroid Injection and Thumb Spica Splint in the Treatment of De Quervain’s Disease
AbstractBackground: De Quervain's disease (DQ) is painful tenosynovitis involving APL & EPB tendons caused by overuse or repetitive activity. Various modalities of treatment of DQ in western population including local corticosteroid injection, splinting or both. However, there is no data regarding the efficacy of these two modalities in Bangladesh. Therefore, the purpose of the study is to compare the effects of intralesional corticosteroid injection and thumb spica splint in the management of De Quervain's disease in this population. Methods: This randomized clinical trial was conducted with 60 adult patients either male or female diagnosed as a case of De Quervain's disease (moderate to severe pain) attending outpatient department of Physical Medicine and Rehabilitation in DMCH forsix month’s period. The patients were randomly assigned into two groups by lottery, i.e. Group-A: Intralesional methyl prednisolone acetate 0.5 ml (20mg) + 0.5 ml of 2%lidocaine, Group-B: Thumb Spica Splint. Intralesional corticosteroid injections were given with 1cc syringe between the synovial sheath and the tendons, during the initial visit. Group-B patients were advised to use Thumb Spica splint continuously. The patients of both groups were advised to follow the ADL instructions for the affected hand as much as possible. Outcome was measured by Visual Analogue Scale (VAS) and Patient Rated Wrist Evaluation (PRWE) scale. Every patient was assessed every week for 6 weeks. The level of significance was assessed with the help of paired t-test and chi-square test where necessary.Results: Among the 60 patients (30 in each group), highest numbers of patients were found to be in 41-45 year-age group (35%) followed by 28.33% in 46-50 years group with mean age of 41.77±5.43 years. Male-to-female ratio was 1:7.6. More than half of the patients (53%) had been suffering from the disease in their right hand, 42% in left hand and 5% in both hands. There was no significant difference in pretreatment VAS &PRWE scores between two groups. They show significant mean changes in each of the three follow ups between the two groups of patients (p=<0.001). Intralesional methylprednisolone acetate injection provided pain relief in 83.33% of patients compared to 36.67% in splint group. Conclusion: Intralesional steroids are more effective to relief pain & discomfort than thumb Spica splint in management of moderate to severe De Quervain's disease.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
